These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 33294721)

  • 1. Molecular docking, molecular dynamics, and
    Alnajjar R; Mostafa A; Kandeil A; Al-Karmalawy AA
    Heliyon; 2020 Dec; 6(12):e05641. PubMed ID: 33294721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
    Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):209-217. PubMed ID: 30370429
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
    Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
    J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
    Chowdhury KH; Chowdhury MR; Mahmud S; Tareq AM; Hanif NB; Banu N; Reza ASMA; Emran TB; Simal-Gandara J
    Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33374717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2.
    Ridgway H; Moore GJ; Mavromoustakos T; Tsiodras S; Ligielli I; Kelaidonis K; Chasapis CT; Gadanec LK; Zulli A; Apostolopoulos V; Petty R; Karakasiliotis I; Gorgoulis VG; Matsoukas JM
    Comput Struct Biotechnol J; 2022; 20():2091-2111. PubMed ID: 35432786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
    Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
    J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
    Wang J
    J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    El-Hddad S; Sobhy M; Ayoub A; El-Adl K
    J Biomol Struct Dyn; 2023 Nov; 41(19):9267-9281. PubMed ID: 36399002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment.
    Heimfarth L; Dos Santos MA; Barreto-Filho JA; Barreto AS; Macedo FN; Araújo AAS; Martins-Filho P; Scotti MT; Scotti L; Quintans-Júnior LJ
    EXCLI J; 2021; 20():252-275. PubMed ID: 33628162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MM-GBSA calculations and molecular dynamics.
    Mohammed AO; Abo-Idrees MI; Makki AA; Ibraheem W; Alzain AA
    Struct Chem; 2022; 33(5):1553-1567. PubMed ID: 35789829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE2 as a potential therapeutic target for pandemic COVID-19.
    Chatterjee B; Thakur SS
    RSC Adv; 2020 Oct; 10(65):39808-39813. PubMed ID: 35515386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
    Kurtz TW; Kajiya T
    Vasc Health Risk Manag; 2012; 8():133-43. PubMed ID: 22399858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bio-Guided Isolation of SARS-CoV-2 Main Protease Inhibitors from Medicinal Plants: In Vitro Assay and Molecular Dynamics.
    Abdallah HM; El-Halawany AM; Darwish KM; Algandaby MM; Mohamed GA; Ibrahim SRM; Koshak AE; Elhady SS; Fadil SA; Alqarni AA; Abdel-Naim AB; Elfaky MA
    Plants (Basel); 2022 Jul; 11(15):. PubMed ID: 35893619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and
    Banerjee S; Yadav S; Banerjee S; Fakayode SO; Parvathareddy J; Reichard W; Surendranathan S; Mahmud F; Whatcott R; Thammathong J; Meibohm B; Miller DD; Jonsson CB; Dubey KD
    J Chem Inf Model; 2021 Nov; 61(11):5469-5483. PubMed ID: 34666487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.